101246-66-6
中文名稱
苯絲氨酸
英文名稱
PHENSERINE
CAS
101246-66-6
分子式
C20H23N3O2
分子量
337.42
MOL 文件
101246-66-6.mol
更新日期
2024/06/17 21:55:05
101246-66-6 結(jié)構(gòu)式
基本信息
中文別名
苯絲氨酸 英文別名
PHENSERINE(3as-cis)-amate(ester
(-)-Eseroline phenylcarbamate
(-)-N-PHENYLCARBAMOYLESEROLINE
3-b)indol-5-ol,1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo(phenylcarb
1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-pyrrolo[2,3-b]indol-5-ol phenylcarbamate (ester)
(3aS,8aR)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol5-(N-phenylcarbamate)
Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, 5-(N-phenylcarbamate), (3aS,8aR)-
物理化學(xué)性質(zhì)
熔點151-152 °C
沸點468.7±45.0 °C(Predicted)
密度1.228±0.06 g/cm3(Predicted)
儲存條件2-8°C
溶解度H2O：<2毫克/毫升
酸度系數(shù)(pKa)13.05±0.70(Predicted)
形態(tài)固體
顏色米白色
苯絲氨酸價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-103374 | 苯絲氨酸 Phenserine | 101246-66-6 | 10mM * 1mLin DMSO | 1559元 |
| 2024/11/08 | HY-103374 | 苯絲氨酸 Phenserine | 101246-66-6 | 5mg | 2100元 |
| 2024/11/08 | HY-103374 | 苯絲氨酸 Phenserine | 101246-66-6 | 10mg | 3500元 |
常見問題列表
生物活性
Phenserine ((-)-Eseroline phenylcarbamate) 是 Physostigmine 的衍生物，是一種有效的，非競爭性，長效和選擇性的 AChE 抑制劑。Phenserine 可減少 β-淀粉樣蛋白前體蛋白 (APP) 和 β-淀粉樣肽 (Aβ) 的形成。Phenserine 可改善認知能力并減輕阿爾茨海默氏病的進展。靶點
AChE; β-amyloid precursor protein; β-amyloid peptide
體外研究
Phenserine (1-25 μM; 48 hours; CHO APP 751SW cells) treatment CHO APP 751SW cell shows 18.6% reduction in cells treated with 10 μM of Phenserine, while 25 μM concentration of Phenserine reduces APP level by 51.4%.
Western Blot Analysis
| Cell Line: | CHO APP 751SW cells |
| Concentration: | 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM |
| Incubation Time: | 48 hours |
| Result: | 8.6% reduction in cells treated with 10 μM, while 25 μM concentration reduces APP level by 51.4%. |
體內(nèi)研究
Phenserine (1-4 mg/kg; intraperitoneal injection; for 4 days; male Fischer-344 rats) treatment improves learning when cholinergic function has been impaired in a spatial memory task.
| Animal Model: | Male Fischer-344 rats (5 months old) induced by scopolamine |
| Dosage: | 1 mg/kg, 2 mg/kg, 4 mg/kg |
| Administration: | Intraperitoneal injection; for 4 days |
| Result: | Improved morris water maze performance of scopolamine-treated rats.. |